Borealis Biosciences
Industry
- Pharmaceuticals
- Biotechnology
- Drug Discovery Technologies
- Antisense, Oligonucleotides
See more in Biomedtracker
Latest on Borealis Biosciences
Scrip
• By Amanda Micklus
One key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up
In Vivo
• By Amanda Micklus
A key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of
Scrip
• By Mandy Jackson
Venture capital mega-rounds of $100m or more have surged in 2024 and the trend has continued in December, with announcements on 19 December that Ottimo Pharma’s series A round brought in more than $14